Navigation Links
Transition Therapeutics Announces Second Quarter Fiscal 2009 Financial Results
Date:2/11/2009

pment program for TT-223, Transition has performed two Phase I studies to expand the dose ranges for TT-223. The first study, a single ascending dose study of TT-223 in healthy volunteers and the second study, a multiple ascending dose study of TT-223 have both been completed.

In August 2008, Transition and its collaboration partner Lilly initiated a Phase II trial evaluating TT-223 in type 2 diabetes patients receiving metformin and/or thiazolidinediones (TZDs) which completed enrolling patients in February 2009. Transition and its development partner Lilly are in discussions regarding the timing and planning of another clinical study with TT-223 in combination with a GLP1 analogue in type 2 patients.

    Financial Review
    ----------------

Results of Operations

For the three-month period ended December 31, 2008, the Company recorded a net loss of $4,873,270 ($0.21 per common share) compared to a net loss of $1,552,208 ($0.07 per common share) for the three-month period ended December 31, 2007.

For the six-month period ended December 31, 2008, the Company recorded a net loss of $9,906,066 ($0.43 per common share) compared to a net loss of $5,651,186 ($0.25 per common share) for the six-month period ended December 31, 2007.

The increase in net loss of $3,321,062 or 214% for the three-month period ended December 31, 2008 and $4,254,880 or 75% for the six-month period ended December 31, 2008 is due to an increase in research and development expenses primarily resulting from an increase in clinical development costs related to ELND005 (AZD-103). The increase in net loss for the three and six-month periods ended December 31, 2008 is also attributed to an increase in general and administrative expense and decreases in interest income, revenue, and gain on note receivable. The increase in net loss was partially offset by foreign exchange gains resulting from the Company's US dollar inves
'/>"/>

SOURCE Transition Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine news :

1. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
2. Transition Therapeutics Receives Remaining Upfront Payment from Elan Corporation, plc
3. Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2008 Financial Results on Wednesday, November 14, at 8:30 A.M. EST
4. New UIC center to study end-of-life transition
5. Seabrook House Opens Transitional Living Facility: Seabrook West
6. Transition Therapeutics Announces Milestone Payment from Elan
7. Transition Therapeutics Announces Appointment of Vice-President of Business Development
8. Pure Weight Loss Takes Additional Steps To Assure Seamless Transition For Clients
9. Zimmer Spine Introduces New Rigid to Dynamic Stabilization Transition System
10. Bisexuality not a transitional phase among women, according to new research
11. Transition of Behavioral Health Services from WPIC-BV to Heritage Valley Health System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Using quality improvement measures in eight of the 10 ... Group, researchers have found a way to reduce kidney ... , Currently, 7-15 percent of these patients who undergo ... kidney injury, which can result in death or rapid ... dialysis, says a study published in the July issue ...
(Date:7/29/2014)... Historically, Memorial Day kicks off a three ... throughout that time by picnics, barbecues and beach outings. ... the start of a period that will witness a ... 2012 nearly 1.000 people were killed in crashes involving ... Labor Day. , The summer's warmer weather, longer days ...
(Date:7/29/2014)... During his 37 years in dental practice, ... has had a steady stream of college students shadow him ... now gone on to dental school and some are now ... program helps college students find success. , For students interested ... the chance to see a realistic view of what goes ...
(Date:7/29/2014)... 29, 2014 A team of scientists, ... Ethell, PhD, has developed a blood test for Alzheimer’s ... the development of Alzheimer’s disease interventions, according to an ... a puzzle, and this study represents one of several ... the past couple of years,” Ethell said. , The ...
(Date:7/29/2014)... Just months after the recent announcement ... states, the exciting FX family does it again! Michael ... farmboy from Arkansas, is shocking the world with his ... to the masses. This time with their first ... Jamaica. This new office is scheduled to handle ...
Breaking Medicine News(10 mins):Health News:Reducing kidney injury using a quality improvement method 2Health News:Narconon New Life Retreat Launches New Alcohol Prevention Program 2Health News:Arthur Bruce Dental Helps College Students 2Health News:Professor Develops Blood Test for Alzheimer’s Disease Risk 2Health News:Atlanta Special FX Rapidly Expanding Just Opens First International Corporate Office in Jamaica 2
... Decreased muscle strength is associated with difficulty in ... kneeling (SCK) in older adults, according to an ... Physical Therapy (PTJ), the scientific journal ... researchers found that adults with SCK difficulty had ...
... They differ from each other in many ways, and they ... HIV to resist a host of weapons fired at ... emerging. One potential weapon is a small-molecule ... by attacking them through some feature common to an entire ...
... ... a Soho Seminar event that will help you transform the way employees engage inside and ... ... at the Soho Seminars event “Aligning the Corporate and Personal Brand,” hosted by Loyola ...
... effect on heart from androgen deprivation, official says ... with prostate cancer and the physicians who treat ... (ADT) commonly used against the malignancy might increase ... , "There is a substantial amount of data ...
... , PHILADELPHIA , ... GlaxoSmithKline plc will announce its full year financial results for the ... the announcement will be released to the London Stock Exchange at ... www.gsk.com . , Following the announcement, Andrew Witty , ...
... , , Rare, but serious, liver disorder ... 1 The U.S. Food and Drug Administration today announced ... has been reported in some HIV patients taking Videx/Videx EC ... is an antiretroviral medicine first approved by the FDA in ...
Cached Medicine News:Health News:Decreased muscle strength predicts functional impairments in older adults 2Health News:Decreased muscle strength predicts functional impairments in older adults 3Health News:Researchers find 'broad spectrum' antiviral that fights multitude of viruses 2Health News:Researchers find 'broad spectrum' antiviral that fights multitude of viruses 3Health News:7Summits to Present at Soho Seminars 'Alignment of Personal and Corporate Brands' 2Health News:Experts Issue Warning on Prostate Hormone Therapy 2Health News:Experts Issue Warning on Prostate Hormone Therapy 3Health News:GSK 2009 Financial Results Announcement and Teleconference Details 2Health News:FDA Announces Safety Risk Associated with HIV Drug 2
(Date:7/29/2014)...  Roche (SIX: RO, ROG; OTCQX: RHHBY) launched its ... 2014 Clinical Lab Expo today by unveiling two booths ... is partnering with customers to redefine the value of ... day that they,re looking for a partner to help ... and offices," said Jack Phillips , president and ...
(Date:7/29/2014)... DUBLIN , July 29, 2014 ... the "Global Respiratory Devices Market 2014-2018" report ... A respiratory device is a medical ... who is having difficulty in breathing and cannot achieve ... disorders such as cystic fibrosis, asthma, COPD, and ARDS ...
(Date:7/29/2014)... Medical Corporation (Apex, TWSE: 4106), a leading player in the ... is appealing the judgment of the Regional Court of ... that found the headgear of certain mask models infringe a ... against various ResMed patents in major countries. Apex further reiterates ... ResMed filed the lawsuit with the Regional ...
Breaking Medicine Technology:Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 2Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 3Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 4Global Respiratory Devices Market 2014-2018 2Apex Continues Fighting Against Patents to Free Up Competition 2
... -- China Medical Technologies, Inc. (the "Company") (Nasdaq: ... ("IVD") company, today announced that its subsidiary, Beijing GP ... sixth in the Deloitte Technology Fast 50 China 2010 ... molecular diagnostic businesses of the Company. The ...
... Oct. 21 Investigators from Texas Children,s Hospital ... North America came together in Houston to analyze ... the Berlin Heart EXCOR® Pediatric Ventricular Assist Device ... more about the study, see: http://bit.ly/bfrA1J ...
Cached Medicine Technology:China Medical Technologies Announces its Subsidiary, GP Medical, Ranked Sixth in Deloitte Technology Fast 50 China 2010 Program 2Texas Children's Hospital Hosts North American Investigators on Berlin Heart Trial 2Texas Children's Hospital Hosts North American Investigators on Berlin Heart Trial 3Texas Children's Hospital Hosts North American Investigators on Berlin Heart Trial 4
0.5mm 1X2 Teeth with 6mm Tying Platform; in Stainless Steel 125...
... necessary addition to any ... Reichert Trial Frame provides ... smooth controls for quick, ... design, high-quality materials, and ...
... CTS utilizes a small-cone design and ... a complete, shadow-free representation of the ... system that includes the topographer, PC, ... software enables quick and easy access ...
... AL500 incorporates all of the features you ... well as a color display, auto add-lock, ... design fits easily into your existing workspace, ... glare-free viewing at any angle.,Quick and accurate, ...
Medicine Products: